Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 11 entities : Eli lilly and company save search
Better Together: New Licensing and Collaboration Deals to Watch
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: -2.44%
H: 3.61%
C: 2.68%
collaboration license
Inflammatory Bowel Disease Market Is Anticipated to Progress at a CAGR of 8.0% in the APAC Region for the Study Period of 2018 to 2030, Estimates DelveInsight
Published: 2022-04-11 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 3.07%
H: 0.0%
C: -0.32%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 4.5%
H: 0.0%
C: 0.0%
GLPG | News | $29.25 -0.81% -0.82% 190K
|
Health Technology
|
| O: -1.31%
H: 0.06%
C: -2.47%
disease market
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Published: 2022-04-11 (Crawled : 14:20) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
disease dermatitis
Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
Published: 2022-04-11 (Crawled : 13:20) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
antibody program license
Faeth Therapeutics Expands Leadership Team with Thomas Strack as Chief Medical Officer and Virginia Casadas as Head of Clinical Operations
Published: 2022-04-11 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
therapeutics
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.165 -7.17% -7.73% 2.5M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.